Cargando…
Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cells
The PAX3-FOXO1 fusion gene functions as a transactivator and increases expression of many cancer-related genes. These lead to metastases and other unfavorable outcomes for alveolar rhabdomyosarcoma (ARMS) patients. In order to target ARMS with the PAX3-FOXO1 transactivator, we developed an Oncolytic...
Autores principales: | Yoshida, Hideki, Sato-Dahlman, Mizuho, Hajeri, Praveensingh, Jacobsen, Kari, Koodie, Lisa, Yanagiba, Chikako, Shanley, Ryan, Yamamoto, Masato |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749408/ https://www.ncbi.nlm.nih.gov/pubmed/33338875 http://dx.doi.org/10.1016/j.tranon.2020.100997 |
Ejemplares similares
-
CD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancer
por: Sato-Dahlman, Mizuho, et al.
Publicado: (2017) -
Oncolytic Adenoviruses: Strategies for Improved Targeting and Specificity
por: Hajeri, Praveensingh B., et al.
Publicado: (2020) -
Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination
por: Sato-Dahlman, Mizuho, et al.
Publicado: (2020) -
Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma
por: AHN, EUN HYUN, et al.
Publicado: (2013) -
Interferon‐expressing oncolytic adenovirus + chemoradiation inhibited pancreatic cancer growth in a hamster model
por: Shinoda, Shuhei, et al.
Publicado: (2023)